Overview Financials News + Filings Key Docs Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
|
|
AN2 Therapeutics, Inc.
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/03/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 83,337 shares
@ $16.28, valued at
$1.4M
Sold 15,764 shares
@ $16.28, valued at
$256.6k
Sold 4,770 shares
@ $16.07, valued at
$76.7k
Sold 902 shares
@ $16.07, valued at
$14.5k
|
|
| 10/03/2023 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 83,337 shares
@ $16.28, valued at
$1.4M
Sold 15,764 shares
@ $16.28, valued at
$256.6k
Sold 4,770 shares
@ $16.07, valued at
$76.7k
Sold 902 shares
@ $16.07, valued at
$14.5k
|
|
| 09/29/2023 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 707 shares
@ $16.07, valued at
$11.4k
Sold 134 shares
@ $16.07, valued at
$2.2k
Sold 7,160 shares
@ $16.11, valued at
$115.3k
Sold 1,356 shares
@ $16.11, valued at
$21.8k
|
|
| 09/29/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 707 shares
@ $16.07, valued at
$11.4k
Sold 134 shares
@ $16.07, valued at
$2.2k
Sold 7,160 shares
@ $16.11, valued at
$115.3k
Sold 1,356 shares
@ $16.11, valued at
$21.8k
|
|
| 08/25/2023 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 336 shares
@ $16, valued at
$5.4k
Sold 64 shares
@ $16, valued at
$1k
|
|
| 08/25/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 336 shares
@ $16, valued at
$5.4k
Sold 64 shares
@ $16, valued at
$1k
|
|
| 08/22/2023 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 1,777,778 shares
@ $9, valued at
$16M
|
|
| 06/09/2023 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Zakrzewski Joseph S (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| FitzPatrick Margaret M (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Wong Stephanie (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Marks Gilbert Lynn (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Martin Patricia A. (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Spigelman Melvin K (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 06/09/2023 |
4
| Readnour Robin Shane (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 23,742 options to buy
@ $5.91, valued at
$140.3k
|
|
| 05/15/2023 |
4
| Easom Eric (CEO) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 10,000 shares
@ $5.377, valued at
$53.8k
|
|
| 02/24/2023 |
4
| Easom Eric (CEO) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 267,650 options to buy
@ $11.99, valued at
$3.2M
|
|
| 11/14/2022 |
4
| Easom Eric (CEO) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 4,413 shares
@ $15.3248, valued at
$67.6k
Sold 23 shares
@ $15.04, valued at
$345.9 |
|
| 11/07/2022 |
4
| Easom Eric (CEO) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Sold 11,082 shares
@ $15.6725, valued at
$173.7k
Sold 3,083 shares
@ $16.0155, valued at
$49.4k
Sold 8,828 shares
@ $15.7991, valued at
$139.5k
Sold 10,167 shares
@ $15.9049, valued at
$161.7k
Sold 2,036 shares
@ $16.7171, valued at
$34k
|
|
| 11/02/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/28/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/26/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/24/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/05/2022 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 1,809 shares
@ $7.48, valued at
$13.5k
Bought 100 shares
@ $7.99, valued at
$799 |
|
| 07/28/2022 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 14,938 shares
@ $7.71, valued at
$115.2k
Bought 8,281 shares
@ $7.91, valued at
$65.5k
|
|
| 06/24/2022 |
4
| Aziz Kabeer (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Disposed of 26,511 shares
@ $15, valued at
$397.7k
Acquired 26,511 shares
@ $15, valued at
$397.7k
|
|
| 06/24/2022 |
4
| Adjuvant Global Health Technology Fund, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Disposed of 26,511 shares
@ $15, valued at
$397.7k
Acquired 26,511 shares
@ $15, valued at
$397.7k
|
|
| 06/23/2022 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 302 shares
@ $7.99, valued at
$2.4k
|
|
| 06/15/2022 |
4
| RA CAPITAL MANAGEMENT, L.P. (10% Owner) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Bought 20,000 shares
@ $7.9, valued at
$158k
Bought 61,424 shares
@ $7.9676, valued at
$489.4k
|
|
| 05/16/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/16/2022 |
4
| Readnour Robin Shane (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 20,724 options to buy
@ $17.28, valued at
$358.1k
|
|
| 05/16/2022 |
4
| Eckburg Paul (Chief Medical Officer) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 66,000 options to buy
@ $17.28, valued at
$1.1M
|
|
| 05/16/2022 |
4
| Martin Patricia A. (Director) has filed a Form 4 on AN2 Therapeutics, Inc.|
Txns:
| Granted 10,362 options to buy
@ $17.28, valued at
$179.1k
|
|
|
|
|